Huang C M, del Greco F, Quintanilla A, Molteni A
JAMA. 1981 Feb 6;245(5):478-82.
The antihypertensive effects of the oral converting enzyme inhibitor captopril and of propranolol were evaluated in a single-blind trial of 12 weeks in 19 ambulatory men with moderated essential hypertension (supine diastolic blood pressure [DPB], 100 to 120 mm Hg after receiving placebo for two weeks) whose sodium intake was unrestricted. The captopril group included 12 patients and the propranolol group seven. After the initial dose-finding period of four weeks, supine DBP was significantly reduced in eight patients receiving captopril and in four of the patients receiving propranolol. In these patients DBP decreased throughout the following eight weeks. In the remaining patients from each group, DBP was not reduced by either drug given alone at maximum allowable dosages during dose-finding periods, nor by combined administration in following weeks. No adverse side effects attributable to captopril were noted, except in one patient in whom proteinuria developed after seven weeks. Captopril has potential value in the treatment of moderate essential hypertension.
在一项针对19名中度原发性高血压门诊男性患者（在接受两周安慰剂治疗后仰卧位舒张压[DPB]为100至120mmHg）的单盲试验中，评估了口服转换酶抑制剂卡托普利和普萘洛尔的降压效果，这些患者的钠摄入量不受限制。卡托普利组包括12名患者，普萘洛尔组包括7名患者。在最初为期四周的剂量探索期后，接受卡托普利治疗的8名患者和接受普萘洛尔治疗的4名患者的仰卧位舒张压显著降低。在这些患者中，舒张压在接下来的八周内持续下降。在每组其余患者中，在剂量探索期给予最大允许剂量的单一药物时，舒张压未降低，在接下来的几周联合给药时也未降低。除一名患者在七周后出现蛋白尿外，未观察到与卡托普利相关的不良副作用。卡托普利在治疗中度原发性高血压方面具有潜在价值。
